ArticleDermatology reports2025
Generalized bullous drug eruption triggered by ceftriaxone: a case report and literature overview.
Article in Dermatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceftriaxone is a widely used third-generation cephalosporin antibiotic known for its efficacy and safety. However, hypersensitivity reactions, including rare cases of generalized bullous fixed drug eruption (GBFDE), have been reported. We present the case of a 68-year-old female with a history of multiple comorbidities who developed a generalized bullous drug eruption two days after initiating intravenous ceftriaxone for a suspected respiratory infection. Clinical evaluation revealed extensive bullae and erythematous patches sparing mucous membranes, with histopathology confirming drug-induced epidermal changes. Direct immunofluorescence ruled out autoimmune bullous disorders. Prompt discontinuation of ceftriaxone, systemic corticosteroids, and supportive topical treatments led to marked clinical improvement. This case underscores the importance of recognizing rare but severe cutaneous reactions to ceftriaxone. Early diagnosis and intervention are crucial to minimizing complications and ensuring favorable outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.